Back to Search
Start Over
Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease
- Source :
- Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p3723-3723, 1p
- Publication Year :
- 2021
-
Abstract
- Background
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 138
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs58546862
- Full Text :
- https://doi.org/10.1182/blood-2021-149919